AstraZeneca PLC — Regulatory Filings 2018

Oct 1, 2018

6-K 1 a4350c.htm ATACAND AGREEMENT WITH CHEPLAPHARM COMPLETED Document created using Blueprint(R) - powered by Issuer Direct - www.issuerdirect.com Copyright 2018 Issuer Direct Corporation Blueprint

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of Octobe r 2018

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_______

AstraZeneca PLC

INDEX TO EXHIBITS

1.

Atacand Agreement with Cheplapharm Completed

1 October 2018 07:00 BST

Agreement with Cheplapharm for rights to

Atacand in 28 European countries completed

AstraZeneca has completed an agreement with Cheplapharm Arzneimittel GmbH (Cheplapharm) for the commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) in Europe.

Under the terms of the agreement, AstraZeneca has received a payment of $200 million from Cheplapharm. A time-bound payment of $10 million as well as sales-contingent milestones will also be payable. The present value of the upfront and time-bound payments will be reported as Other Operating Income in the company's financial statements in the third quarter of 2018.

AstraZeneca will continue to manufacture and supply Atacand and Atacand Plus under a supply agreement and will continue to commercialise the medicines in all markets where it still holds the rights .

About Atacand

Atacand (candesartan cilexetil) is a selective, AT1 subtype angiotensin II receptor antagonist blocker (ARB) that is indicated for the treatment of hypertension and heart failure. Atacand is also available in Europe as a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide ( Atacand Plus ). Atacand is indicated for the management of hypertension in adults and children/adolescents, as well as heart failure in adults. Atacand Plus is indicated for the management of hypertension when monotherapy is not sufficiently effective. Atacand was developed in collaboration with Takeda. Each company holds the exclusive rights to the product in certain markets. In other markets, Atacand is co-marketed by both parties.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

| Media Relations — Karen
Birmingham | UK/Global | +44 203 749 5634 |
| --- | --- | --- |
| Rob
Skelding | UK/Global | +44 203 749 5821 |
| Matt
Kent | UK/Global | +44 203 749 5906 |
| Gonzalo
Viña | UK/Global | +44 203 749 5916 |
| Jacob
Lund | Sweden | +46 8 553 260 20 |
| Michele
Meixell | US | +1 302 885 2677 |
| Investor Relations | | |
| Thomas
Kudsk Larsen | | +44 203 749 5712 |
| Henry
Wheeler | Oncology | +44 203 749 5797 |
| Christer
Gruvris | Cardiovascular; Metabolism | +44 203 749 5711 |
| Nick
Stone | Respiratory; Renal | +44 203 749 5716 |
| Josie
Afolabi | Other | +44 203 749 5631 |
| Craig
Marks | Finance; Fixed Income | +44 7881 615 764 |
| Jennifer
Kretzmann | Retail Investors | +44 203 749 5824 |
| US
toll-free | | +1 866 381 7277 |

Adrian Kemp

Company Secretary

AstraZeneca PLC

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 01 October 2018

| By: /s/
Adrian Kemp |
| --- |
| Name:
Adrian Kemp |
| Title:
Company Secretary |

page break